Tag Archive: atrial fibrillation (AF)

Dec 19

Patients with atrial fibrillation (AF) who are bridged with low-molecular-weight heparin (LMWH)

Patients with atrial fibrillation (AF) who are bridged with low-molecular-weight heparin (LMWH) or unfractionated heparin during procedures requiring an interruption of oral anticoagulation tend to be at a higher risk of adverse events than patients who are not bridged, suggests a new analysis published in Circulation.

Nov 28

Emergency department treatment of atrial fibrillation (AF)

Emergency department treatment of atrial fibrillation (AF) or flutter in patients with acute underlying medical illness is associated with a six-fold increase in adverse events, suggests a new study published online in Annals of Emergency Medicine.

Nov 17

Patients with atrial fibrillation (AF) treated with rhythm or rate control experience similar improvements in health-related quality of life (HRQoL)

Patients with atrial fibrillation (AF) treated with rhythm or rate control experience similar improvements in health-related quality of life (HRQoL) over 1 year of follow-up, with improvements being slightly greater among those treated with rhythm control, suggests an international observational study published online November 11 in Circulation: Cardiovascular Quality and Outcomes.

Nov 06

Atrial fibrillation (AF) is associated with a more than two-fold increase in the odds for silent cerebral infarction (SCI)

Atrial fibrillation (AF) is associated with a more than two-fold increase in the odds for silent cerebral infarction (SCI), or a stroke that has no outward signs or symptoms, suggests a review published online in Annals of Internal Medicine. Having AF was associated with SCIs in patients with no history of symptomatic stroke (odds ratio …

Continue reading »

Nov 05

Two new studies have provided more data on the bleeding risks among patients with atrial fibrillation (AF)

Two new studies have provided more data on the bleeding risks among patients with atrial fibrillation (AF) treated with dabigatran, with one showing that the oral anticoagulant carries a significantly higher risk of major bleeding, as well as gastrointestinal bleeding, when compared with warfarin. The first report is published in JAMA: Internal Medicine while the …

Continue reading »

Nov 02

New American Heart Association (AHA)/American Stroke Association (ASA) guideline on primary stroke prevention includes recommendations for new oral anticoagulants in patients with atrial fibrillation (AF)

New American Heart Association (AHA)/American Stroke Association (ASA) guideline on primary stroke prevention includes recommendations for new oral anticoagulants in patients with atrial fibrillation (AF), home blood pressure monitoring in patients with hypertension, smoking cessation, nonestrogen oral contraceptives for women experiencing migraine with aura, and the healthy Mediterranean diet for all patients. The updated guideline …

Continue reading »

Nov 01

A US Food and Drug Administration (FDA) advisory panel voted in favor of a novel anticoagulant for the treatment of patients with atrial fibrillation (AF)

A US Food and Drug Administration (FDA) advisory panel voted in favor of a novel anticoagulant for the treatment of patients with atrial fibrillation (AF). The Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 in favor of approving edoxaban, a factor Xa inhibitor, for the prevention of stroke and non–central-nervous-system (CNS) systemic embolism …

Continue reading »

Sep 11

A new proof–of–concept study has demonstrated that contactless video monitoring can identify changes in skin color in the human face during atrial fibrillation (AF)

A new proof–of–concept study has demonstrated that contactless video monitoring can identify changes in skin color in the human face during atrial fibrillation (AF). Detection of these beat-to-beat variations in skin color resulting from changes in blood flow with the cardiac pulsatile signal helped identify episodes of AF with just a few seconds of recorded …

Continue reading »

Sep 04

Rivaroxaban may be as effective and safe as a vitamin–K antagonist (VKA)

Rivaroxaban may be as effective and safe as a vitamin–K antagonist (VKA) when given for only about a week prior to elective cardioversion for atrial fibrillation (AF). Rivaroxaban can be given once daily, doesn’t require INR checks, and does not need a protracted three–week treatment period before the procedure, as with warfarin. The findings were …

Continue reading »

Aug 31

Innovations in Cardiology (IIC) Summit 2014

Dr Rajneesh Kapoor Warfarin continuation better than discontinuation in AF patients Results from the role of coumadin in preventing thromboembolism in 1584 patients with atrial fibrillation (AF) undergoing catheter ablation (COMPARE) randomized trial published in Circulation 2014 Jun 24;129(25):2638–44 show that warfarin discontinuation was the strong predictor of periprocedural thromboembolism. Performing catheter ablation of AF …

Continue reading »

Older posts «